Navigation Links
Spectrum Pharmaceuticals to Present at the Biotechnology Industry Organization Investor Forum
Date:10/9/2007

IRVINE, Calif., Oct. 9 /PRNewswire-FirstCall/ -- Spectrum Pharmaceuticals, Inc., (Nasdaq: SPPI) announced today that it will present an overview of the Company on Wednesday, October 10, 2007, at 4:45 p.m. Pacific, at the BIO Investor Forum, being held at the Palace Hotel in San Francisco, California. Spectrum's presentation will be held in the Sea Cliff room.

The live webcast of Spectrum's presentation will be available at http://www.spectrumpharm.com. Replays will be available for 30 days.

About Spectrum Pharmaceuticals

Spectrum Pharmaceuticals acquires, develops and commercializes a diversified portfolio of oncology drug candidates that meet critical health challenges for which there are few other treatment options. The company's pipeline includes promising early and late-stage drug candidates with unique formulations and mechanisms of action that address the needs of seriously ill patients, such as at-home chemotherapy and new treatment regimens for refractory disease. For more information, please visit our website at http://www.spectrumpharm.com.

Forward-looking statement -- This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements include but are not limited to statements that relate to our business and its future, Spectrum's ability to identify, acquire, develop and commercialize its portfolio of drug candidates, the Company's promising pipeline, and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include the possibility that our existing and new drug candidates, may not prove safe or effective, the possibility that our existing and new drug candidates may not receive approval from the FDA, and other regulatory agencies in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that our efforts to acquire or in-license and develop additional drug candidates may fail, our lack of revenues, our limited marketing experience, our dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in the Company's reports filed with the Securities and Exchange Commission. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law.

COMPANY CONTACTS MEDIA CONTACT

Russell Skibsted Susan Neath

SVP & Chief Business Officer Porter Novelli Life Sciences

619-849-6007

Paul Arndt

Manager, Investor Relations

949-788-6700


'/>"/>
SOURCE Spectrum Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Tigecycline – New Generation Tetracycline With Broad Spectrum Antibacterial Activit
2. Simple Eye Movement Test For Early Detection Of Fetal Alcohol Spectrum Disorder
3. Lack Of Social Skills Linked To Autism Spectrum Disorder (ASD)
4. Broad Spectrum Antibiotic Available for Antibiotic Resistant Bacteria
5. Fetal Alcohol Spectrum Disorder in Children Can Be Diagnosed With Eye Movement Tests
6. Younger Siblings of Children With Autism Spectrum Disorders Score Low
7. Bipolar Spectrum Disorder may Be Under-recognized for Spectrum Disorder: Study
8. Supply of Radiopharmaceuticals Hampered by Attacks
9. FDA approves Watson Pharmaceuticals Oxytrol patch
10. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
11. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... May 05, 2016 , ... Qrono Inc. , ... a development collaboration with the Australian critical medicine company, Phebra Pty Ltd. ... , LAI medicines can offer improved therapeutic benefits over oral formulations, including better ...
(Date:5/5/2016)... ... May 05, 2016 , ... The ... electronic cigarettes, requiring e-cigarette manufacturers to submit their products through an arduous federal ... all vaping products that entered the market since February 15, 2007. That would ...
(Date:5/5/2016)... FL (PRWEB) , ... May 05, 2016 , ... ... in Tampa to offer patients with non-valvular atrial fibrillation (A-Fib) an alternative to ... Implant. Since first offering the procedure in April of 2015, Florida Hospital Pepin ...
(Date:5/5/2016)... ... May 05, 2016 , ... This weekend, from Friday, May 6 - Sunday, May 8, ... terrain at the first Team Semper Fi Mountain Bike Camp, hosted in conjunction with ... bike legends Mark Weir and Jason Moeschler, who’ll share pro tips with the injured veterans ...
(Date:5/5/2016)... ... 2016 , ... Phycologia – While it is ... researchers Juntian Xu and Kunshan Gao tested the magnitude of this phenomenon on ... photosynthetically active radiation (i.e. the white light in our visible spectrum) was not ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... 2016 Research and ... Acute lymphocytic Leukemia Market and Competitive Landscape ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Market and Competitive Landscape Highlights 2016, provides ... products, Acute Lymphocytic Leukemia epidemiology, Acute Lymphocytic ...
(Date:5/3/2016)... DUBLIN , May 4, 2016 ... the "Global Cancer Stem Cell Therapy Market Outlook ... (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,Recombinant technology has ... therapeutics are expected to be developed in coming years. ... these techniques. Cancer stem cell therapies are also expected ...
(Date:5/3/2016)... , May 3, 2016 ACME ... Whelan and Delaware County Councilman ... Nasal Spray in all ACME pharmacies across ... for Disease Control and Prevention (CDC), naloxone has saved 26,463 lives ... officers in Delaware County were authorized to ...
Breaking Medicine Technology: